Terumo India, the Indian arm of Japan-based medtech firm Terumo Corporation, has recently announced the launch of Occlusafe™ and LifePearl™, intended for use in the management of liver cancer.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with more than 20,000 cases getting added every year in India. HCC can be treated with management approaches ranging from surgical resection to minimally invasive options.

Embolisation is one such minimally invasive management option. The most common type of Embolization is Transcatheter Arterial Chemo-Embolization (TACE), a clinical-guideline recommended, minimally invasive management option for intermediate stage liver cancer.

For the first time in India, Terumo has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer. With Occlusafe™, Terumo’s B-TACE device, patients benefit from more precise and targeted delivery of chemotherapy drug to the tumour. 

Another value addition to be introduced in the area of liver cancer care is LifePearl™. It helps release chemotherapeutic drug in a controlled and sustained manner at the targeted tumour site inside the liver. 

Occlusafe™ and LifePearl™ are known to improve clinical outcomes for liver cancer patients treated with TACE.